Effect-X Biopharma

Effect-X Biopharma is a biotechnology company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies, with a specific focus on molecular glues and PROTACs. The company leverages its proprietary platform to design high-potency small molecules that recruit E3 ligases to degrade disease-relevant proteins previously deemed undruggable. Headquartered in Suzhou with additional R&D operations in the United States, Effect-X focuses on addressing unmet needs in oncology and immunology. Their pipeline includes several lead candidates targeting GSPT1 and other critical transcription factors for the treatment of hematological malignancies and solid tumors. The company is backed by prominent venture capital firms and aims to bridge global innovation in the TPD space.